Attention Deficit Hyperactivity Disorder

Chapter

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder that affects 4–8% of the population across the life span. Up to 90% of those with ADHD have at least one comorbid condition that may be more critical to the child’s or adolescent’s health than is the ADHD. Those with neurodevelopmental disorders are at high risk for ADHD. Management involves psychological therapy often in conjunction with pharmacologic treatment. Non-drug-related management strategies include appropriate educational placement, parent training, biofeedback, social skills training, support groups, psychotherapy, and/or cognitive–behavioral therapy. The emphasis in this chapter is on the pharmacologic approach that includes psychostimulants, antidepressants, alpha-2 agonists, and a norepinephrine reuptake inhibitor. Management of these patients should emphasize a multimodal approach with careful long-term follow-up by the clinician.

Keywords

Autism Spectrum Disorder Attention Deficit Hyperactivity Disorder Tourette Syndrome Oppositional Defiant Disorder Attention Deficit Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Greydanus DE, Pratt HD, Patel DR. Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult. Dis Mon. 2007;53(3):1–59.Google Scholar
  2. 2.
    Still G. The Coulstonian lectures on some abnormal physical conditions in children. Lecture 1. Lancet. 1902;1:1008–12.Google Scholar
  3. 3.
    Clements SD. Minimal brain dysfunction in children: terminology and identification. Washington, DC: United States Department of Health, Education, and Welfare; 1966.Google Scholar
  4. 4.
    Ounsted C. The hyperkinetic syndrome in epileptic children. Lancet. 1955;269(6885):303–11.PubMedCrossRefGoogle Scholar
  5. 5.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000. pp. 85–93.Google Scholar
  6. 6.
    Greydanus DE, Pratt HD. Attention deficit hyperactivity disorder. In: Greydanus DE, Pratt HD, Patel DR, editors. Behavioral pediatrics. 2nd ed. Lincoln, NE: iUniverse Publishing; 2006. pp. 107–42.Google Scholar
  7. 7.
    Wolraich ML, Felice ME. The classification of child and adolescent mental diagnoses in primary care: diagnostic and statistical manual for primary care (DSM PC): child and adolescent version. Elk Grove Village, IL: American Academy of Pediatrics; 1986. pp. 93–110.Google Scholar
  8. 8.
    Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2:104–13.PubMedGoogle Scholar
  9. 9.
    Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716–23.PubMedCrossRefGoogle Scholar
  10. 10.
    Katragadda S, Schubiner H. ADHD in children, adolescents, and adults. Prim Care Clin Office Pract. 2007;34(4):111.Google Scholar
  11. 11.
    Lara C, Fayyad J, de Graaf R, et al. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol Psychiatry. 2009;65(1):46–54.PubMedCrossRefGoogle Scholar
  12. 12.
    Biederman J, Farone SV. Attention-deficit/hyperactivity disorder. Lancet. 2005;366:237–48.PubMedCrossRefGoogle Scholar
  13. 13.
    Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005;57:1215–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Bush G. Attention-deficit/hyperactivity disorder and attention networks. Neuropsychopharmacol. 2010;35:278–300.CrossRefGoogle Scholar
  15. 15.
    Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy. 2009;29(6):656–79.PubMedCrossRefGoogle Scholar
  16. 16.
    Faraone SV, Khan SA. Candidate gene studies of attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67(Suppl 8):13–20.PubMedGoogle Scholar
  17. 17.
    Sharp SI, McQuillin A, Gurling HM. Genetics of attention-deficit hyperactivity disorder (ADHD). Neuropharmacology. 2009;57(7–8):590–600.PubMedCrossRefGoogle Scholar
  18. 18.
    Rommelse NN, Altink ME, Fliers EA, et al. Comorbid problems in ADHD: degree of association, shared endophenotypes, and formation of distinct subtypes. Implications for a future DSM. J Abnorm Child Psychol. 2009;37(6):793–804.PubMedCrossRefGoogle Scholar
  19. 19.
    Elia J, Ambrosini P, Berrettini W. ADHD characteristics: I. Concurrent co-morbidity patterns in children and adolescents. Child Adolesc Psychiatry Ment Health. 2008;2(1):15–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Gadow KD, DeVincent CJ, Schneider J. Comparative study of children with ADHD only, autism spectrum disorder + ADHD, and chronic multiple tic disorder + ADHD. J Atten Dis. 2009;12(5):474–85.CrossRefGoogle Scholar
  21. 21.
    Reiersen AM, Constantino JN, Todd RD. Co-occurrence of motor problems and autistic symptoms in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008;47(6):662–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Murray MJ. Attention-deficit/hyperactivity disorder in the context of autism spectrum disorders. Curr Psychiatr Rep. 2010;Aug;12:33–40.Google Scholar
  23. 23.
    Simonoff E, Pickles A, Charman T, et al. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47(8):921–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Konofal E, Lecendreux M, Cortese S. Sleep and ADHD. Sleep Med. 2010;11(7):652–8.PubMedCrossRefGoogle Scholar
  25. 25.
    LaJoie J, Miles DK. Treatment of attention-deficit disorder, cerebral palsy, and mental retardation in epilepsy. Epilepsy Behav. 2002;3(5S):42–48.PubMedCrossRefGoogle Scholar
  26. 26.
    Bottcher L, Flachs EM, Uldall P. Attentional and executive impairments in children with spastic cerebral palsy. Dev Med Child Neurol. 2010;52(2):e42–e47.PubMedCrossRefGoogle Scholar
  27. 27.
    Connor DF, Steeber J, McBurnett K. A review of attention-deficit/hyperactivity disorder complicated by symptoms of oppositional defiant disorder or conduct disorder. J Dev Behav Pediatr. 2010;31(5):427–40.PubMedCrossRefGoogle Scholar
  28. 28.
    Hummer TA, Kronenberger WG, Wang Y, et al. Executive functioning characteristics associated with ADHD comorbidity in adolescents with disruptive behavior disorders. J Abnorm Child Psychol. 2010;Aug;6:21–26.Google Scholar
  29. 29.
    Trani MD, Casini MP, Capuzzo F, et al. Executive and intellectual functions in attention-deficit/hyperactivity disorder with and without comorbidity. Brain Dev. 2010;Aug;6:33–40.Google Scholar
  30. 30.
    Germano E, Gagliano A, Curatolo P. Comorbidity of ADHD and dyslexia. Dev Neuropsychol. 2010;35(5):475–93.PubMedCrossRefGoogle Scholar
  31. 31.
    Barnard-Brak L, Sulak TN, Fearon DD. Coexisting disorders and academic achievement among children with ADHD. J Atten Dis. 2010;Jun;7:21–26.Google Scholar
  32. 32.
    McNamara J, Vervaeke SL, Willoughby T. Learning disabilities and risk-taking behaviors in adolescents: a comparison of those with and without comorbid attention-deficit/hyperactivity disorder. J Learn Disabil. 2008;41(6):561–74.PubMedCrossRefGoogle Scholar
  33. 33.
    Forbes F. Improving recognition and management of ADHD. Practitioner. 2010;254(1728):34–38.PubMedGoogle Scholar
  34. 34.
    Goraya JS, Cruz M, Valencia I, et al. Sleep study abnormalities in children with attention deficit hyperactivity disorder. Pediatr Neurol. 2009;40(1):42–46.PubMedCrossRefGoogle Scholar
  35. 35.
    Greydanus DE, Pratt HD. Attention deficit/hyperactivity disorder in adolescents. In: Greydanus DE, Patel DR, Pratt HD, editors. Essential adolescent medicine. New York, NY: McGraw-Hill Medical Publishing; 2006. pp. 751–68.Google Scholar
  36. 36.
    Greydanus DE, Calles JL Jr, Patel DR. Pediatric and adolescent psychopharmacology: a practical manual for pediatricians. Cambridge: Cambridge University Press; 2008.CrossRefGoogle Scholar
  37. 37.
    Kunwar A, Dewan M, Faraone SV. Treating common psychiatric disorders associated with attention-deficit/hyperactivity disorder. Expert Opin Pharmacother. 2007;8(5):555–62.CrossRefPubMedGoogle Scholar
  38. 38.
    Daviss WB. A review of co-morbid depression in pediatric ADHD: etiology, phenomenology, and treatment. J Child Adolesc Psychopharmacol. 2008;18(6):565–71.PubMedCrossRefGoogle Scholar
  39. 39.
    Biederman J, Monteaux MC, Spencer T, et al. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics. 2009;123(1):71–78.CrossRefGoogle Scholar
  40. 40.
    Gau SS, Ni HC, Shang CY, et al. Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder. Aust NZ J Psychiatry. 2010;44(2):135–43.CrossRefGoogle Scholar
  41. 41.
    Barkley RA, editor. Attention deficit hyperactivity disorder: a handbook for diagnosis. 3rd ed. New York, NY: Guilford; 2006.Google Scholar
  42. 42.
    Culpepper L. Primary care treatment of attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67(Suppl 8):51–58.PubMedGoogle Scholar
  43. 43.
    Greydanus DE, Sloane MA, Rappley MD. Psychopharmacology of ADHD in adolescents. Adolesc Med. 2002;13:599–624.PubMedGoogle Scholar
  44. 44.
    Greydanus DE, Pratt HD, Sloane MA, et al. Attention-deficit/hyperactivity disorder in children and adolescents: Interventions for a complex costly clinical conundrum. Pediatr Clin North Am. 2003;50:1049–92.PubMedCrossRefGoogle Scholar
  45. 45.
    Greydanus DE:. Psychopharmacology of ADHD in adolescents: Quo vadis? Psychiatr Times. 2003;20:5–9.Google Scholar
  46. 46.
    Schepis TS, Marlowe DB, Forman FG. The availability and portrayal of stimulants over the internet. J Adolec Health. 2008;42:458–65.CrossRefGoogle Scholar
  47. 47.
    Jensen PS, Hinshaw SP, Swanson JM, Greenhill LL, Conners CK, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr. 2001;22:60–73.PubMedCrossRefGoogle Scholar
  48. 48.
    National Institute of Mental Health (NIMH). Attention deficit hyperactivity disorder. NIMH, NIH Publication No. 01-4589, 2001. Available at: http://www.nimh.nih.gov/publicat/helpchild.cfm
  49. 49.
    National Institute of Mental Health. NIMH research on treatment for attention deficit hyperactivity disorder (ADHD): The multimodal treatment study. Questions and answers. Washington, DC: NIMH, 2000. Available at: http://www.nimh.nih.gov/events/mtaqa.cfm
  50. 50.
    MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: 24 month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004;113(4):754–61.CrossRefGoogle Scholar
  51. 51.
    Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry. 1937;94:577–85.Google Scholar
  52. 52.
    Knobel M, Wolman MB, Mason E. Hyperkinesis and organicity in children. Arch Gen Psychiatry. 1959;81:94–105.Google Scholar
  53. 53.
    Clarke SD. ADHD in adolescence. J Adolesc Health. 2000;l27:77–8.CrossRefGoogle Scholar
  54. 54.
    Schubiner H, Robin AL, Young J. Attention-deficit/hyperactivity disorder in adolescent males. Adolesc Med. 2003;14:663–76.PubMedGoogle Scholar
  55. 55.
    Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacology of attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(6):642–57.PubMedCrossRefGoogle Scholar
  56. 56.
    Staufer WB, Greydanus DE. Attention-deficit/hyperactivity disorder psychopharmacology for college students. Pediatr Clin North Am. 2005;52:71–84.PubMedCrossRefGoogle Scholar
  57. 57.
    Kaplan G, Newcorn JH, Ivanov IS. Pharmacologic management of ADHD in children and adolescents. Int J Child Adolesc Health. 2010;3(2):22–35.Google Scholar
  58. 58.
    Wilens TE. Mechanism of action of agents used in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67(Suppl 8):32–38.PubMedGoogle Scholar
  59. 59.
    Gilchrist RH, Arnold LE. Long-term efficacy of ADHD: pharmacotherapy in children. Pediatr Ann. 2008;37(1):46–51.PubMedCrossRefGoogle Scholar
  60. 60.
    Solanto MV, Arnsten AFT, Castellanos FX:. The neuroscience of stimulant drug action in ADHD. In: Solanto MV, Arnsten AFT, Castellanos FX, editors. Stimulant Drugs and ADHD. London: Oxford University Press; 2001. pp. 355–79.Google Scholar
  61. 61.
    Greydanus DE, Kaplan G, Antshel KM. Attention deficit hyperactivity disorder: neuropsychologic and pharmacologic considerations. In: Noggle CA, Dean RS, editors. The neuropsychology of psychopharmacology. New York, NY: Springer; 2010.Google Scholar
  62. 62.
    Reiff MI, Stein MT. ADHD evaluation and diagnosis: a practical approach to office practice. Pediatr Clin North Am. 2003;50:1019–48.PubMedCrossRefGoogle Scholar
  63. 63.
    Ter-Stepanian M, Grizenko N, Zappitelli M, Joober R. Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders. Can J Psychiatry. 2010;55(5):305–12.PubMedGoogle Scholar
  64. 64.
    Drugs for Treatment of ADHD. Treat Guidelines. Med Lett. 2006;4:77.Google Scholar
  65. 65.
    Focalin XR for ADHD. Med Lett. 2009;51:22–24.Google Scholar
  66. 66.
    Chavez B, Sopko MA Jr, Ehret MJ, et al. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Ann Pharmacother. 2009;43(6):1084–95.PubMedCrossRefGoogle Scholar
  67. 67.
    Marcus SC, Wan GJ, Kenmner JE, et al. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2005;159:572–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Faraone SV. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention-deficit hyperactivity disorder. Expert Opin Pharmacother. 2008;9(9):1565–74.PubMedCrossRefGoogle Scholar
  69. 69.
    Findling RL, Ginsberg LD, Jain R, Gao J. Effectiveness, safety, and tolerability of Lisdexamfetamine dimesylate in children with attention-deficit hyperactivity disorder: an open-label, dose-optimization study. J Child Adolesc Psychopharmacol. 2009;19(6):649–62.PubMedCrossRefGoogle Scholar
  70. 70.
    Mattingly G. Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults. CNS Spectr. 2010;15(5):315–25.PubMedGoogle Scholar
  71. 71.
    Brams M, Moon E, Pucci M, López FA. Duration of oral long-acting stimulant medications for ADHD throughout the day. Curr Med Res Opin. 2010;26(8):1809–25.PubMedCrossRefGoogle Scholar
  72. 72.
    Cowles BJ. Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder. Ann Pharmacother. 2009;43(4):669–76.PubMedCrossRefGoogle Scholar
  73. 73.
    Perrin JM, Friedman RA, Knilans TD. The Black Box Working Group and the Section on Cardiology and Cardiac Surgery. Pediatrics. 2008;122:451–53.PubMedCrossRefGoogle Scholar
  74. 74.
    Vitiello B, Towbin K. Stimulant treatment of ADHD and risk of sudden death in children. Am J Psychiatr. 2009;166(9):955–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Wilens TE, Prince JB, Spencer TJ, Biderman J. Stimulants and sudden death: what is a physician to do? Pediatrics. 2006;118(3):1215–19.PubMedCrossRefGoogle Scholar
  76. 76.
    Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulants in youths. Am J Psychiatry. 2009;166(9):992–1001.PubMedCrossRefGoogle Scholar
  77. 77.
    McCarthy S, Cranswick N, Potts L, et al. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents, and young adults using the general practice research database. Drug Saf. 2009;32(11):1089–96.PubMedCrossRefGoogle Scholar
  78. 78.
    Warren AE, Hamilton RM, Bélanger SA, et al. Cardiac risk assessment before the use of stimulant medications in children and youth: a joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry. Can J Cardiol. 2009;25(11):625–30.PubMedCrossRefGoogle Scholar
  79. 79.
    Kaufmann R, Goldberg-Stern H, Shuper A. Attention-deficit disorders and epilepsy: incidence, causative relations, and treatment possibilities. J Child Neurol. 2009;24(6):727–33.PubMedCrossRefGoogle Scholar
  80. 80.
    Hamoda HM, Guild DJ, Gumlak S, et al. Association between attention-deficit/hyperactivity disorder and epilepsy in pediatric populations. Expert Rev Neurother. 2009;9(12):1747–54.PubMedCrossRefGoogle Scholar
  81. 81.
    Schubert R. Attention deficit disorder and epilepsy. Pediatr Neurol. 2005;32(1):1–10.PubMedCrossRefGoogle Scholar
  82. 82.
    Varley CK. Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms and clinical implications. Paediatr Drugs. 2001;3:613–27.PubMedCrossRefGoogle Scholar
  83. 83.
    Wilens TE, Farone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179–85.PubMedCrossRefGoogle Scholar
  84. 84.
    Ivanov I, Pearson A, Kaplan G, Newcorn J. Treatment of adolescent ADHD and comorbid substance abuse. Int J Child Adoles Health. 2010;3(2):45–60.Google Scholar
  85. 85.
    Kollins SH. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin. 2008;24(5):1345–57.PubMedCrossRefGoogle Scholar
  86. 86.
    Swanson JM and the MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113:762–9.CrossRefGoogle Scholar
  87. 87.
    Greydanus DE, Merrick J. Psychopharmacology in children, adolescents, and adults with attention deficit hyperactivity disorder. In: Gordon SM, Mitchell AE, editors. Attention deficit hyperactivity disorder. New York, NY: Nova Science Publishers; 2009. pp. 257–72.Google Scholar
  88. 88.
    Bloch MH, Leckman JF. Clinical course of Tourette Syndrome. J Psychosom Res. 2009;67(6):497–501.PubMedCrossRefGoogle Scholar
  89. 89.
    Cavanna AE, Servo S, Monaco F, Robertson MM. The behavioral spectrum of Gilles de la Tourette syndrome. J Neuropsychiatry Clin Neurosci. 2009;21(1):13–23.PubMedCrossRefGoogle Scholar
  90. 90.
    Jankovic J. Tourette’s syndrome. N Engl J Med. 2001;345:1184–92.PubMedCrossRefGoogle Scholar
  91. 91.
    Roessner V, Becker A, Banaschewski T, Rothenberger A. Executive functions in children with chronic tic disorders with/without ADHD: new insights. Eur Child Adolesc Psychiatry. 2007;16(Suppl 1):36–44.PubMedCrossRefGoogle Scholar
  92. 92.
    Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48(9):884–93.PubMedCrossRefGoogle Scholar
  93. 93.
    Atomoxetine (Strattera) for ADHD. Med Lett. 2003;45:11–12.Google Scholar
  94. 94.
    Atomoxetine: Strattera revisited. Med Lett. 2004;46:65.Google Scholar
  95. 95.
    Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with ADHD: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896–901.PubMedCrossRefGoogle Scholar
  96. 96.
    Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203–26.PubMedCrossRefGoogle Scholar
  97. 97.
    Waxmonsky JG. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults. Essent Psychopharmacol. 2005;6(5):262–76.PubMedGoogle Scholar
  98. 98.
    May DE, Kratochvil CJ. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs. 2010;70(1):15–40.PubMedCrossRefGoogle Scholar
  99. 99.
    Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord. 2008;11(4):470–81.PubMedCrossRefGoogle Scholar
  100. 100.
    Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity, and impulsiveness. CNS Drugs. 2009;23(Suppl 1):43–49.PubMedCrossRefGoogle Scholar
  101. 101.
    Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13(12):1047–55.PubMedGoogle Scholar
  102. 102.
    Connor DF, Rubin J. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents. Drugs Today (Barc). 2010;46(5):299–314.Google Scholar
  103. 103.
    Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155–65.PubMedCrossRefGoogle Scholar
  104. 104.
    Arnsten AF, Scahill L, Finding RL. Alpha-2 adrenergic receptor agonists for treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol. 2007;17(4):393–406.PubMedCrossRefGoogle Scholar
  105. 105.
    Daviss WB. Bupropion for adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:307–14.PubMedCrossRefGoogle Scholar
  106. 106.
    Reimherr FW, Hedges DW, Strong RE, et al. Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial. Neuropsychiatr Dis Treat. 2005;1(3):245–51.PubMedGoogle Scholar
  107. 107.
    Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs. 2009;23(Suppl 1):21–31.PubMedCrossRefGoogle Scholar
  108. 108.
    Clayton AH. Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? Expert Opin Pharmacother. 2007;8(4):457–66.PubMedCrossRefGoogle Scholar
  109. 109.
    Verbeeck W, Tuinier S, Bekkering GE. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systemic review. Adv Ther. 2009;26(2):170–84.PubMedCrossRefGoogle Scholar
  110. 110.
    Pityaratstian N:. Advances in alternative pharmacotherapy of ADHD. J Med Assoc Thai. 2005;88(Suppl 4):S357–S62.PubMedGoogle Scholar
  111. 111.
    Armodafinil for wakefulness. Med Lett Dr Ther. 2010;52:61–2.Google Scholar
  112. 112.
    Turner DC, Clark L, Dowson J, et al. Modafinil improves cognition and response in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004;55:1031–40.PubMedCrossRefGoogle Scholar
  113. 113.
    Keen D, Hadijikoumi I. ADHD in children and adolescents. Clin Evid (Online). 2008;Oct 2;PMID:19445793.Google Scholar
  114. 114.
    Richardson AJ, Montgomery P. The Oxford-Durham Study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics. 2005;115(5):1360–6.PubMedCrossRefGoogle Scholar
  115. 115.
    Hamre HJ, Witt CM, Kienle GS, et al. Anthroposophic therapy for attention deficit hyperactivity: a two-year prospective study in outpatients. Int J Gen Med. 2010;3:239–53.PubMedCrossRefGoogle Scholar
  116. 116.
    Olfson M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care. 2004;10(4 Suppl):S117–S24.PubMedGoogle Scholar
  117. 117.
    Greydanus DE, Pratt HD et al. Attention-deficit/hyperactivity disorder in children and adolescents: interventions for a complex costly clinical conundrum. Pediatr Clin North Am. 2003;50:1061–1062.Google Scholar
  118. 118.
    Greydanus DE, Pratt HD et al. Psychopharmacology of ADHD in adolescents. Adolesc Med. 2002;13:604.Google Scholar
  119. 119.
    Greydanus DE, Pratt HD et al. Psychopharmacology of ADHD in adolescents. Adolesc Med. 2002;13:607.Google Scholar
  120. 120.
    Greydanus DE, Pratt HD et al. Psychopharmacology of ADHD in adolescents. Adolesc Med. 2002;13:615.Google Scholar
  121. 121.
    Greydanus DE, Pratt HD, et al. Attention-deficit/hyperactivity disorder in children and adolescents: interventions for a complex costly clinical conundrum. Pediatr Clin North Am. 2003;50:1079.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Department of Pediatrics and Human DevelopmentKalamazoo Center for Medical Studies, Michigan State University College of Human MedicineKalamazooUSA

Personalised recommendations